Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × LB100 × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 1273 Cisplatin 1209 Radiotherapy 1146 Paclitaxel 1132 Carboplatin 1074 Gemcitabine 1047 Docetaxel 978 Bevacizumab 909 Fluorouracil 764 Doxorubicin 688 Capecitabine 652 Dexamethasone 641 Rituximab 635 Oxaliplatin 599 Etoposide 577 pembrolizumab 565 Irinotecan 550 Filgrastim 537 Cytarabine 502 Leucovorin 497 Nivolumab 478 Vincristine 437 Bortezomib 412 Cetuximab 411 Prednisone 406 Trastuzumab 398 Erlotinib Hydrochloride 397 Surveys and Questionnaires 390 Methotrexate 369 Sorafenib 362

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Lixte Biotechnology Holdings, Inc.

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡